Imugene (IUGNF) Price & Analysis

Compare

39 Followers

IUGNF Stock Chart & Stats

$0.18

>-$0.01(-3.57%)

At close: Jan 08 4:00 PM EST

$0.18

>-$0.01(-3.57%)

Day’s Range― - ―

52-Week Range$0.03 - $1.47

Previous CloseN/A

Volume3.00K

Average Volume (3M)16.95K

Market Cap

$58.09M

Enterprise Value$70.70M

Total Cash (Recent Filing)$21.94M

Total Debt (Recent Filing)$10.65M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Mar 04, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding321,515,630

10 Day Avg. Volume11,247

30 Day Avg. Volume16,948

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.15

Price to Sales (P/S)21.99

P/FCF Ratio-1.07

Enterprise Value/Market Cap1.22

Enterprise Value/Revenue16.08

Enterprise Value/Gross Profit16.08

Enterprise Value/Ebitda-1.05

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Clinical-stage PipelineA multi-asset immuno-oncology pipeline provides multiple 'shots on goal' across distinct modalities (oncolytic virus and vaccine approaches). This structural diversification reduces binary risk from any single program, supports partnership interest, and preserves upside as different trials advance over months.

Conservative Capital StructureLow leverage and a moderate equity base give the company financial flexibility to fund ongoing R&D without heavy interest burden. This makes the balance sheet more resilient to clinical trial timelines and reduces near-term refinancing risk versus highly leveraged peers.

Positive Free Cash Flow To Net IncomeA FCF-to-net-income ratio above 1 suggests periods where cash generation compares favorably to accounting losses, indicating some cash efficiency. Over a medium horizon this can help preserve runway, enabling continued trial investment or more orderly fundraising.

Bears Say

Severe Revenue DeclineA steep revenue contraction signals the absence of meaningful recurring commercial sales and weak operational scale. Over 2-6 months this heightens reliance on external funding, increases dilution risk, and limits internal resources to advance multiple clinical programs concurrently.

Persistent Losses And Poor ReturnsDeep negative margins and severely negative ROE indicate capital is not generating returns and the business consumes equity value. Structurally, this undermines investor confidence, complicates partnership economics, and raises the probability of future equity raises to sustain development.

Negative Operating Cash FlowContinued cash outflows from operations are a durable constraint for a clinical-stage biotech: they shorten runway and force dependence on capital markets. Over months this limits discretionary investment in trials, increases financing pressure, and can lead to program prioritization or delays.

Imugene News

Imugene Issues 1.7 Million New Shares on Convertible Note Conversion

The latest update is out from Imugene ( ($AU:IMU) ). Imugene Limited has issued 1,736,111 fully paid ordinary...

18d ago

Imugene Posts Strong Azer-cel Data and Cuts Costs as It Advances Toward Pivotal Trial

Imugene ( ($AU:IMU) ) has issued an update. Imugene reported strong Phase 1b clinical data for its allogeneic...

18d ago

Imugene Issues 1.74 Million New Shares on Convertible Note Conversion

Imugene ( ($AU:IMU) ) has issued an update. Imugene Limited has issued 1,736,111 fully paid ordinary shares to...

1M ago

Imugene Seeks ASX Quotation for 1.7 Million New Shares After Option Conversions

Imugene ( ($AU:IMU) ) has issued an update. Imugene Limited has applied to the ASX for quotation of...

1M ago

Imugene Cancels Over One Million Lapsed Options and RSUs

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene Limited has reported the cessation of several classes of...

1M ago

Imugene Seeks ASX Quotation for 929,427 Newly Issued Shares

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has applied for quotation on the ASX of...

1M ago

Imugene COO Bradley Glover Resigns as Company Moves to Ensure Seamless Transition

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene has announced the resignation of Chief Operating Officer Dr...

2M ago

Imugene Issues 1.74 Million New Shares on Convertible Note Conversion

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has issued 1,736,111 fully paid ordinary shares to...

2M ago

Imugene Seeks ASX Quotation for 1.74 Million New Shares

Imugene ( ($AU:IMU) ) has shared an announcement. Imugene Limited has applied for quotation on the ASX of...

2M ago

Imugene Issues New Unquoted Equity Under Employee Incentive Scheme

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene Limited has notified the market of the issue of...

2M ago

IUGNF FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest stock price was $0.03 and its highest was $1.47 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is $58.09M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Mar 04, 2026 which is in 15 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Aug 27, 2025. The company reported -$0.067 earnings per share for the quarter, beating the consensus estimate of -$0.241 by $0.174.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate is -0.24.

How many shares outstanding does Imugene have?

Imugene has 321,515,630 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -$0.067 in its last earnings report, beating expectations of -$0.241. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in IUGNF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Underperform

Blogger Sentiment

Bullish

IUGNF Sentiment 76%
Sector Average ―

Technicals

Fundamentals

Return on Equity

-83.09%

Trailing 12-Months

Asset Growth

-45.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.